Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir

K Akinosoglou, G Schinas, C Gogos - Viruses, 2022 - mdpi.com
Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

[HTML][HTML] Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022

MM Shah - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …

Update on COVID-19 therapy in pediatric age

S Esposito, G Autore, A Argentiero, G Ramundo… - Pharmaceuticals, 2022 - mdpi.com
With the extension of the COVID-19 pandemic, the large use of COVID-19 vaccines among
adults and the emergence of SARS-CoV-2 variants means that the epidemiology of COVID …

Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022

MM Shah, B Joyce, ID Plumb, S Sahakian… - American Journal of …, 2023 - amjtransplant.org
Paxlovid associated with decreased hospitalization rate among adults with COVID-19 —
United States, April–September 2022 - American Journal of Transplantation Skip to Main …

[HTML][HTML] Estimated impact of oral nirmatrelvir; ritonavir on reductions in hospitalizations and associated costs within high-risk COVID-19 patients in the US

R Sandin, C Harrison, F Draica, TL Wiemken, C Ma… - 2022 - europepmc.org
Background: SARS-CoV-2 (COVID-19) virus is estimated to cost the United States (US)
economy trillions of dollars over the next decade. Mass immunization has played a major …